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incremental cost per QALY gained of $50,000 to $60,000, com-The cost-effectiveness of maintaining higher hemoglobin tar-
pared with a hemoglobin target of 9.5 to 10.5 g/dL. Aiminggets with erythropoietin in hemodialysis patients.
for hemoglobin targets in excess of 12.0 g/dL is associatedBackground. There is uncertainty regarding the appropriate
with unfavorable cost-effectiveness ratios and should not betarget hemoglobin level in hemodialysis patients treated with
undertaken based on current data.erythropoietin (EPO).
Methods. We sought to determine the incremental cost-effec-
tiveness of prescribing EPO to maintain different target hemo-
globin levels, by incorporating the impact of EPO on health- Erythropoietin (EPO) deficiency commonly accompa-related quality-of-life (HRQOL) issues and adopting the
nies chronic kidney disease [1], and if untreated, leadsperspective of the health care purchaser. We evaluated the
to severe anemia in the majority of patients with end-prescription of EPO to maintain target hemoglobin levels of
11.0 to 12.0, 12.0 to 12.5, and 14.0 g/dL, compared with 9.5 to stage renal disease (ESRD). Most patients receiving he-
10.5 g/dL. Model outputs were quality-adjusted life expectancy modialysis for ESRD currently receive recombinant hu-
and costs. man EPO for treatment of anemia [2]. However, EPOResults. The base case analysis estimated intravenous EPO
is an expensive therapy, since annual costs due to its userequirements to be 3523, 5078, 6097, and 9341 units three times
for ESRD in the United States exceed $1 billion US [2].per week to maintain targets of 9.5 to 10.5, 11.0 to 12.0, 12.0 to
12.5, and 14.0 g/dL, respectively. The cost per quality-adjusted While it is widely accepted that patients with renal
life year (QALY) gained for the 11.0 to 12.0 g/dL target vs. anemia should receive EPO treatment, there is contro-
9.5 to 10.5 g/dL was $55,295 US. For the 12.0 to 12.5 g/dL versy regarding the appropriate target hemoglobin level.target compared to 11.0 to 12.0 g/dL, and 14.0 g/dL target
A large body of evidence from observational studiescompared to 12.0 to 12.5 g/dL, the costs per QALY gained
demonstrates that near-normal achieved hemoglobinwere $613,015 US and $828,215 US, respectively. In sensitivity
analysis, clinically implausible reductions in hospitalization or concentration (12.0 g/dL) correlates with improved
EPO requirements associated with the two higher hemoglobin outcomes in hemodialysis patients, including lower mor-
targets were required to make their incremental cost per QALY tality and hospitalization rates [3–6]. However, data fromgained $100,000 US.
randomized trials in which EPO was used to raise hemo-Conclusion. Dosing intravenous EPO to achieve hemoglo-
globin levels to different target levels are more equivocal.bin targets of 11.0 to 12.0 g/dL appears to be associated with
Nonetheless, American and Canadian clinical practice
guidelines both recommend that hemoglobin in dialysis
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patients be maintained between 11.0 to 12.0 g/dL [7, 8],cost-effectiveness analysis.
and European guidelines suggest a mean patient hemo-
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14.0 g/dL in hemodialysis patients, compared with a more the baseline analysis, costs and QALYs were discounted
at an annual rate of 3% [15]. Costs were calculated inconservative level of 9.5 to 10.5 g/dL. In addition, we
sought to determine what mortality or health-related 2001 United States dollars. All analyses were performed
using DATA PRO (TreeAge Software, Inc., Williams-quality-of-life (HRQOL) benefit would be necessary to
justify the increased costs associated with the higher he- town, VT, USA), and SAS 8.2 (SAS Institute, Cary, NC,
USA).moglobin targets, using a set of hypothetical cost-effective-
ness thresholds ($20,000 US/QALY, $50,000 US/QALY,
Clinical effectsand $100,000 US/QALY) [10].
Randomized trials have reported improved clinical
outcomes associated with EPO use, as compared with
METHODS
placebo [12]. Although data from observational studies
Population have demonstrated reduced mortality in patients with
higher achieved hemoglobin levels [3, 6], these individu-We performed an incremental cost-effectiveness anal-
ysis comparing treatment with EPO to three different als actually required less EPO than those with lower
levels of hemoglobin [2, 3], suggesting that clinical char-goal hemoglobin ranges. In the baseline analysis, we
evaluated a simulated cohort of prevalent hemodialysis acteristics differed substantially between groups. It is
doubtful that multivariate adjustment is capable of cor-patients whose characteristics were representative of a
typical dialysis center in the United States in terms of recting for the bias inherent in such analyses. Thus, we
used data from randomized trials wherever possible inage, gender, race, and comorbidity [11].
constructing our decision analysis. Data from random-
Treatment alternatives ized trials were located by a systematic review of elec-
tronic databases (MEDLINE, Cochrane Library), ab-We specified all treatment strategies in terms of target
hemoglobin rather than hemoglobin level achieved, as stracts from major nephrology meetings, and the authors’
personal files.the former is more reflective of clinical practice and of
the data obtained in randomized trials. The reference
Quality of lifehemoglobin target was selected as 9.5 to 10.5 g/dL, since
prescribing EPO to keep hemoglobin levels in this range Quality of life is substantially reduced among people
with ESRD, compared with the general population. Util-reduces the need for blood transfusions and has been
shown to improve selected domains of HRQOL com- ity is a measure of the preference for a specific health
outcome, which usually acts as a single marker ofpared with placebo [12].
We considered three treatment alternatives to the ref- HRQOL. Utility ranges from 0, representing the worst
imaginable health, to 1, representing perfect health. Forerence strategy in this analysis. The first was a hemoglo-
bin target of 11.0 to 12.0 g/dL, as recommended by pub- baseline analyses, the average utility score for hemodial-
ysis patients treated to the 11.0 to 12.0 g/dL target (0.621,lished American Kidney/Dialysis Outcomes Quality
Initiatives (K/DOQI) and Canadian clinical practice 95% CI 0.574, 0.668) was estimated from a recent study
of hemodialysis patients (target hemoglobin 11.0 to 12.0guidelines [7, 8]. The second was a mean hemoglobin of
12.0 to 12.5 g/dL, as recommended by the European Best g/dL) [16], which is similar to previous work. Based on
the results of the only randomized study that has com-Practice guidelines [9]. The third strategy was based on
a target hemoglobin of 14.0 g/dL, which continues to be pared quality of life between the 9.5 to 10.5 g/dL and
the 11.0 to12.0 g/dL targets, we estimated that utilityadvocated in the literature [13].
scores will be lower for the 9.5 to10.5 g/dL target by
Model 7.4% compared with the 11.0 to12.0 g/dL target [12].
This assumption is favorable to the 11.0 to12.0 g/dL tar-We used decision analysis to model the costs and clini-
cal benefits of treating hemodialysis patients with EPO get, given that the observed difference in utility scores
between the different target hemoglobin groups in thedoses adjusted to achieve the four different goal hemo-
globin ranges. The perspective of the economic evalua- randomized trial was not statistically significant [12].
Although there is no evidence that utility scores con-tion was that of the health care purchaser (i.e., Medicare
in the United States); only direct health service costs tinue to improve once hemoglobin levels rise above 12.0
g/dL, physical function scores on the SF-36 (a widelywere analyzed.
A Markov process [14] was used to model yearly tran- used index of HRQOL) increase in a linear fashion up
to a normal hematocrit [17], and high hemoglobin targetssitions between the three possible clinical states, “alive
on hemodialysis,” “alive with a renal transplant,” and (14.0 g/dL) are associated with improvements in se-
lected dimensions of HRQOL in certain patients (ab-“dead” over the lifetime of the patient, assuming that
transplant recipients would not require EPO treatment. stract; Strombom U, et al, J Am Soc Nephrol 10:269A,
1999). To deal with this uncertainty, we estimated utilityThe model outputs were expected QALYs and costs. In
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Table 1. Baseline risks of clinical outcomes and resource use associated with erythropoietin (EPO) administered
to a target hemoglobin of 9.5 to 10.5 g/dL
Variable Estimate Source
Annual mortality risk for patients (reference case) 244.4/1000 [21]
Annual number of hospitalization days (reference case) 13.9 days/patient-years [21]
Average physician claims for United States hemodialysis patients per year $10,322 [21]
Annual rate of vascular access failure (reference case), adjusted for distribution of access types AVF (25%): 0.074/HD year [34]
PTFE (75%): 0.216/HD year
Average utility score for in-center hemodialysis patients (11.0 to 12.0 g/dL target) 0.621 [16]
Average annual use of intravenous iron for in-center hemodialysis patients (reference case)a 1500 mg/12 months [3]
Rate of transplantation 0.054 [21]
Average utility score for patient with functioning renal transplant 0.816 [23]
Mortality among renal transplant recipients [35]
Year 1 0.08
Years 2 and subsequent 0.038
Average cost of in-center hemodialysis per year $26,692 [22]
Average cost of outpatient carea for hemodialysis patients $5,682 [22]
Average cost of hospitalization for United States hemodialysis patients, per day (per year) $1469 ($20,418) [21]
Yearly cost of transplantation [23]
Year 1 $45,077
Years 2 and subsequent $18,955/year
Abbreviations are: AVF, arteriovenous fistula; HD, hemodialysis; PTFE, polytetrefluoroethylene.
a Includes cost of emergency room visits, day surgery, all diagnostic imaging and laboratory tests, and outpatient medications (excluding EPO and intravenous
iron)
scores for the 12.0 to 12.5 g/dL and the 14.0 g/dL strate- rate ($1 US $1.45 CAN). All cost estimates are shown
in Table 1.gies using two distinct methods (Appendix 1).
In the baseline analysis, the cost of EPO was deter-
Mortality mined based on the current allowed Medicare charge of
$10 per 1000 units, regardless of copayments and deduct-The annual mortality of hemodialysis patients treated
to a goal hemoglobin of 11.0 to 12.0 g/dL was estimated ibles [19]. For simplicity, each hemoglobin target was
considered as the midpoint of its range (i.e., target ofusing data from the United States Renal Data System
(USRDS) (Table 1) [11]. We assumed no survival differ- hemoglobin 11.0 to 12.0 g/dL  11.5 g/dl). Because the
model was potentially sensitive to EPO requirements,ence for patients treated with either of the higher dose
EPO strategies, in agreement with results from two large we derived these parameters by three methods for each
of the hemoglobin targets (Appendix 2).randomized studies [17, 18].
Intravenous iron supplementation was assumed to be
Risk of hospitalization iron sucrose, and iron requirements for each strategy
were determined using a similar process. Costs of ironNo randomized trial has reported a reduction in hospi-
sucrose were obtained from the 2001 Red Book [20].talization associated with intermediate or high hemoglo-
The annual cost of hospitalization and physician claimsbin levels in hemodialysis patients [17](abstract; Foley
for each hemodialysis patient was based on MedicareRN et al, J Am Soc Nephrol 13:432A, 2002). For the
payment data [21]. The annual cost of in-center hemodi-base case analysis, we therefore assumed that rates of
alysis and outpatient care (excluding EPO and intrave-hospitalization were equivalent between study arms.
nous iron) was taken from a recent North American
Other clinical effects costing study [22]. The cost of renal transplantation was
taken from a recent prospective North American studyAlthough large randomized trials have shown that
EPO increases vascular access failure rates compared [23].
with placebo [12, 17], this relationship may not apply
Sensitivity analysiswhen comparing the reference case to the 11.0 to 12.0
As any model involves assumptions and uncertainties,g/dL or 12.0 to 12.5 g/dL targets. The base case analysis
extensive sensitivity analyses were carried out to assesstherefore assumed that access failure rates were not af-
the effect of varying baseline estimates within clinicallyfected by hemoglobin target, which is favorable to the
plausible ranges. In particular, we performed detailedhigher hemoglobin targets.
sensitivity analysis for the two variables (EPO dose and
Resource use estimates of HRQOL for each strategy), which had the
largest impact on the results of our model. Given theWhere applicable, costs were converted to 2001 United
States dollars using the January 2001 currency exchange widespread use and acceptance of higher dose EPO strat-
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Table 2. Predicted dose of intravenous and subcutaneous erythropoietin required to achieve varying levels of target hemoglobina
EPO dose estimate A EPO dose estimate B
(predicted intravenous (predicted subcutaneous
Target hemoglobin EPO useb) units/dialysis session EPO useb) units/dialysis session
9.5–10.5 g/dL 3523 (2650–4684) 3030 (2279–4028)
11.0–12.0 g/dL 5078 (4128–6247) 4367 (3550–5372)
12.0–12.5 g/dL 6097 (4967–7484) 5243 (4272–6436)
14.0 g/dL 9341 (6954–12547) 8033 (5980–10790)
a See Appendix 2 for details of calculation
b 95% CI in parentheses
Fig. 1. Predicted dose of intravenous and
subcutaneous erythropoietin (EPO) required
to achieve different hemoglobin targets.
Table 3. Cost-effectiveness of different hemoglobin targetsegies, we have attempted to make the model favorable
for use in hemodialysis patients (in United States dollars),
to the status quo wherever uncertainty exists. considering the base case analysis only [utility method 1,
erythropoietin (EPO) dose estimate A]
Incremental Incremental costRESULTS
Comparator strategies QALYs gained per QALY gained
EPO requirements
11.0–12.0 g/dL vs. 9.5–10.5 g/dL 0.146 $55,295
12.0–12.5 g/dL vs. 11.0–12.0 g/dL 0.009 $613,015Based on the primary method of estimation (EPO
14.0 g/dL vs. 12.0–12.5 g/dL 0.020 $828,215dose method A), intravenous EPO requirements were
QALY is quality-adjusted life year.3523, 5078, 6097, and 9341 units per dialysis session for
9.5 to 10.5 g/dL, 11.0 to 12.0 g/dL, 12.0 to 12.5 g/dL,
and 14.0 g/dL targets, respectively (Table 2, Fig. 1). The 11.0 to 12.0 g/dL strategies. The cost per QALY gained
intravenous EPO use predicted by the model for the by adopting the 11.0 to 12.0 g/dL target compared to the
14.0 g/dL strategy was slightly lower than the actual EPO 9.5 to 10.5 g/dL target was $55,295 (Table 3). For the
use in the largest available randomized trial [17]. As 12.0 to 12.5 g/dL target compared with 11.0 to 12.0 g/dL,
expected, subcutaneous EPO requirements were lower and 14.0 g/dL target compared with 12.0 to 12.5 g/dL,
than intravenous EPO requirements for all target hemo- the cost to achieve an extra QALY was $500,000 in
globin levels (Table 2, Fig. 1). both cases (Table 3).
Since the 11.0 to 12.0 g/dL target is widely accepted
Sensitivity analysis: EPO requirementsin the United States, we compared the predicted intrave-
nous EPO use associated with this strategy to actual We performed additional analyses to explore the im-
EPO use among American hemodialysis patients. Our pact of changes in EPO requirements on our results.
model predicted EPO requirements of 5078 units/treat- Administering EPO subcutaneously rather than intrave-
ment, similar to actual EPO use (4972 units/treatment) [2]. nously did not significantly change the results of our
analysis, since the incremental cost per QALY gained by
Baseline cost-effectiveness analysis the 11.0 to 12.0 g/dL strategy was $47,877, and remained
Under the base case scenario (EPO dose estimate $500,000 for the two higher hemoglobin targets (Table
A, utility method 1), the highest increment in expected 4, utility method 1). As expected, increasing the effi-
ciency of the subcutaneous route (relative to the intrave-QALYs was observed between the 9.5 to 10.5 g/dL and
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Table 4. Scenario analyses: The cost-effectiveness of different hemoglobin targets for use in hemodialysis patients (in United States dollars),
considering two different routes of erythropoietin (EPO) use and two different utility estimates
Intravenous EPO use Subcutaneous EPO use
(EPO dose estimate A) (EPO dose estimate B)
Utility method 1 (nonlinear, base case)
Incremental QALYs gained
11.0–12.0 g/dL vs. 9.5–10.5 g/dL 0.146 0.146
12.0–12.5 g/dL vs. 11.0–12.0 g/dL 0.009 0.009
14.0 g/dL vs. 12.0–12.5 g/dL 0.020 0.020
Incremental cost per QALY gained
11.0–12.0 g/dL vs. 9.5–10.5 g/dL $55,295 $47,877
12.0–12.5 g/dL vs. 11.0–12.0 g/dL $613,015 $529,960
14.0 g/dL vs. 12.0–12.5 g/dL $828,215 $715,028
Utility method 2 (linear)a
Incremental QALYs gained
11.0–12.0 g/dL vs. 9.5–10.5 g/dL 0.146 0.146
12.0–12.5 g/dL vs. 11.0–12.0 g/dL 0.073 0.073
14.0 g/dL vs. 12.0–12.5 g/dL 0.170 0.170
Incremental cost per QALY gained
11.0–12.0 g/dL vs. 9.5–10.5 g/dL $55,295 $47,877
12.0–12.5 g/dL vs. 11.0–12.0 g/dL $71,739 $62,020
14.0 g/dL vs. 12.0–12.5 g/dL $97,460 $83,816
QALY is quality-adjusted life year.
a This estimate was derived by assuming that utility increased directly and proportionately with target hemoglobin
As a point of reference, the routine treatment of 59-year-old male patients with ischemic heart disease and hypercholesterolemia using simvastatin is associated
with a cost per QALY gained of $6200 [36].
nous route) reduced the incremental cost per QALY the estimate of EPO dose per treatment, the relative im-
provements in utility associated with each hemoglobinassociated with the higher hemoglobin targets if EPO
was administered subcutaneously (Table 5). target, and the annual cost of annual hospitalization for
each hemoglobin target.When the estimate of intravenous EPO requirements
was reduced by 25%, the incremental cost per QALY In general, clinically implausible changes in these vari-
ables were required to significantly improve the cost-for the 11.0 to 12.0 g/dL strategy fell to $42,049. However,
the incremental cost per QALY for the 12.0 to 12.5 effectiveness of the higher hemoglobin strategies. For
instance, comparing the 11.0 to 12.0 g/dL and 9.5 to 10.5and 14.0 g/dL strategies remained high at $464,702 and
$626,094 respectively, as compared with the next most g/dL strategies, the difference in EPO use per treatment
would need to be reduced by 65% (i.e., from 1555 unitseffective alternative. Using the lower limit of the 95%
CI for the model’s estimate of EPO requirements (rather to 550 units) to change the cost per QALY gained to
$20,000. Similarly, comparing the 11.0 to 12.0 g/dL andthan the estimate itself) did not materially affect our
conclusions (Table 5). 9.5 to 10.5 g/dL strategies, a 20% improvement in utility
(similar to the improvement seen with renal transplanta-
Sensitivity analysis: Utility gains tion) would be needed to change the cost per QALY
gained to $20,000.We also considered the less likely scenario in which
utility scores continued to improve in linear fashion with We considered the impact of hospitalization sepa-
rately. Comparing the 11.0 to12.0 g/dL, 12.0 to12.5 g/dL,the target hemoglobin (Table 4, utility method 2). In this
scenario, comparing the 12.0 to 12.5 g/dL target with and 14.0 g/dL targets with the 9.5 to 10.5 g/dL target,
hospitalization would need to be reduced by 13%, 21%,11.0 to 12.0 g/dL and the 14.0 g/dL target with 12.0 to
12.5 g/dL, the cost to achieve an extra QALY was less and 45%, respectively, to offset the increased cost of
EPO associated with these strategies. Comparing thethan using utility method 1 ($50,000 to $100,000), regard-
less of the estimate used for the EPO dose (Table 4). 14.0 g/dL target with current North American recom-
mendations (i.e., 11.0 to 12.0 g/dL), to achieve a cost per
Multiway sensitivity analyses QALY gained of$100,000 using the base case analysis,
overall hospitalization rates would need to be reducedWe performed one-way and multiway sensitivity anal-
yses on the base case model (EPO dose estimate A/utility by 30%.
If we assumed a 10% improvement in survival formethod 1) varying the estimates of all other uncertain
variables. In one way, sensitivity analysis comparing the patients treated with EPO to higher hemoglobin targets,
the cost per QALY gained varied25% for all compari-11.0 to 12.0 g/dL target with the 9.5 to 10.5 g/dL target,
incremental cost per QALY gained varied  50% only sons. The cost per QALY estimates were not sensitive
to changes in the baseline utility score for the referencefor striking variations within the following three variables:
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Table 5. Sensitivity analyses: The cost-effectiveness of different hemoglobin targets for use in hemodialysis patients
(in United States dollars), considering the base case
Incremental cost
per QALY gained
Base case
11.0–12.0 g/dL vs. 9.5–10.5 g/dL $55,295
12.0–12.5 g/dL vs. 11.0–12.0 g/dL $613,015
14.0 g/dL vs. 12.0–12.5 g/dL $828,215
Assuming dose requirements for subcutaneous erythropoietin
(EPO) are 32% lower than intravenousa
11.0–12.0 g/dL vs. 9.5–10.5 g/dL $38,340
12.0–12.5 g/dL vs. 11.0–12.0 g/dL $423,174
14.0 g/dL vs. 12.0–12.5 g/dL $569,500
Assuming that dose requirements were reflected by the lower
limit of the 95% CI of the modelb
11.0–12.0 g/dL vs. 9.5–10.5 g/dL $48,627
12.0–12.5 g/dL vs. 11.0–12.0 g/dL $469,072
14.0 g/dL vs. 12.0–12.5 g/dL $569,500
Actual cost of EPO $8 per 1000 unitsc
11.0–12.0 g/dL vs. 9.5–10.5 g/dL $44,698
12.0–12.5 g/dL vs. 11.0–12.0 g/dL $494,365
14.0 g/dL vs. 12.0–12.5 g/dL $666,518
Hospitalization rates reduced in high hemoglobin groupsd
11.0–12.0 g/dL vs. 9.5–10.5 g/dL Dominant (lower costs/higher QALYs
compared to low hemoglobin strategy)
12.0–12.5 g/dL vs. 11.0–12.0 g/dL Dominated
14.0 g/dL vs. 12.0–12.5 g/dL $1,143,718
Intravenous iron requirements increased by 50%, compared
with base case
11.0–12.0 g/dL vs. 9.5–10.5 g/dL $57,607
12.0–12.5 g/dL vs. 11.0–12.0 g/dL $632,779
14.0 g/dL vs. 12.0–12.5 g/dL $847,946
Baseline utility score in hemodialysis patients at lower limit
of 95% CIe
11.0–12.0 g/dL vs. 9.5–10.5 g/dL $59,822
12.0–12.5 g/dL vs. 11.0–12.0 g/dL $663,210
14.0 g/dL vs. 12.0–12.5 g/dL $896,030
Baseline utility score in hemodialysis patients at upper limit
of 95% CIe
11.0–12.0 g/dL vs. 9.5–10.5 g/dL $51,404
12.0–12.5 g/dL vs. 11.0–12.0 g/dL $569,884
14.0 g/dL vs. 12.0–12.5 g/dL $769,942
Increased access failure rates associated with high hemoglobin
strategiesf
11.0–12.0 g/dL vs. 9.5–10.5 g/dL $56,137
12.0–12.5 g/dL vs. 11.0–12.0 g/dL $613,015
14.0 g/dL vs. 12.0–12.5 g/dL $834,376
Best case scenario for higher hemoglobin arms: Linear
improvement in quality of life AND reduction in
hospitalization at higher hemoglobin targetsg
11.0–12.0 g/dL vs. 9.5–10.5 g/dL $21,971
12.0–12.5 g/dL vs. 11.0–12.0 g/dL $36,194
14.0 g/dL vs. 12.0–12.5 g/dL $64,963
Using a range of clinically plausible costs for outpatient hemodialysis obtained from both Canadian and American sources did not affect these results (data not
shown). QALY is quality-adjusted life year.
a In a large randomized trial [37], the mean reduction in EPO dose associated with the subcutaneous route was 32% (95% CI, 14% to 50%). The base case in the
current analysis assumed that EPO doses would be 14% lower than intravenous.
b The model of EPO requirements versus target hemoglobin level produced estimates of EPO dose with 95% CI for the subcutaneous and intravenous routes
(Table 3). The base case used the estimated EPO requirements themselves; this sensitivity analysis used the lower limit of the 95% CI to address the possibility that
the model overestimated EPO requirements.
c The allowed Medicare charge for EPO is $10 per 1000 units, but coinsurance and deductibles can amount to a maximum of 20% of the allowed charge and not
all hemodialysis patients have insurance.
d The base case assumed no change in hospitalization associated with higher hemoglobin strategies, based on the result of a large randomized trial. In this sensitivity
analysis, we have used unadjusted hospitalization rates from an observational study [24] after stratification by achieved (rather than prescribed) hemoglobin level:
annual hospital days were assumed to be 16.2, 11.6, 14.3, and 14.3 for 9.5 to 10.5 g/dL, 11.0 to 12.0 g/dL, 12.0 to 12.5 g/dL, and 14.0 g/dL strategies, respectively.
e The base case assumed that the mean utility score for hemodialysis patients was 0.621 based on the result of a recent study (95% CI, 0.574–0.668) [16].
f The base case assumed that there was no increased risk of access failure associated with the higher hemoglobin targets. For this sensitivity analysis, relative risks
for access failure of 1.0, 1.174, 1.174, and 1.347 were used for the 9.5 to 10.5 g/dL, 11.0 to 12.0 g/dL, 12.0 to 12.5 g/dL, and 14.0 g/dL strategies, respectively, based
on the relative risk of access failure observed in the largest published randomized trial [17].
g In this scenario, which was highly favorable to higher hemoglobin targets, we assumed that quality of life improved in a linear fashion up to a normal hemoglobin
(utility method 2) and that hospitalization was reduced proportionately at the higher hemoglobin targets (reductions in hospitalization of 7.5%, 11.5%, and 20%
respectively for the 11.0 to 12.0 g/dL, 12.0 to 12.5 g/dL and 14.0 g/dL groups, compared with the 9.5 to 10.5 g/dL target).
Tonelli et al: Cost-effectiveness of erythropoietin 301
strategy, rates of access thrombosis, to changes in intra- scores was required, we believe that this would be un-
founded, since all assumptions were favorable to highervenous iron requirements, changes in the cost of outpa-
tient hemodialysis, or to plausible variations in the cost hemoglobin targets. This suggests that complete data on
utility would not qualitatively change our conclusions,of EPO (Table 5). Changes in the discount rate, baseline
mortality rate, or type of iron supplementation used also since the cost per QALY for the higher hemoglobin
strategies would probably become less favorable. How-did not affect the results.
ever, additional randomized trials, which carefully evalu-
Cost implications ate HRQOL due to different levels of target hemoglobin,
would further inform this debate.Considering only the additional EPO and intravenous
iron requirements, the incremental cost per year re- Proponents of the two higher EPO targets might argue
that the unfavorable cost per QALY ratios associatedquired to maintain patients with ESRD at 11.0 to 12.0
g/dL, 12.0 to 12.5 g/dL, and 14.0 g/dL targets compared with these strategies would be offset by lower expendi-
tures related to hospitalization or by reduced mortality.with 9.5 to 10.5 g/dL is $2540, $4550, and $9400, respec-
tively. Since there are approximately 210,000 hemodialy- Our data suggest that this is not the case. For the 14.0
g/dL strategy to be associated with a marginally accept-sis patients in the United States, of whom 95% receive
EPO [2], the additional cost implied by each of these able cost-effectiveness ratio of$100,000/QALY, hospi-
talization rates for patients treated to this hemoglobinguidelines in the United States alone is $530 million,
$955 million, and $2.0 billion, respectively. level would have to be reduced by 30% compared with
the reference target.
In a randomized trial comparing normalization of he-
DISCUSSION
moglobin with the 9.5 to 10.5 g/dL hemoglobin target
We found that the cost per QALY gained by adopting in people with established cardiovascular disease (who
the 11.0 to 12.0 g/dL strategy as compared with the 9.5 account for the majority of current hemodialysis pa-
to 10.5 g/dL strategy was approximately $55,000 when tients), hospitalization rates were unchanged in the nor-
intravenous EPO was used. As progressively higher he- mal hemoglobin group (overall, 4% increase; 95% CI,
moglobin targets were considered, the incremental cost 3% reduction to 12% increase) [17]. In a second trial,
per QALY gained rose, and was greater than $500,000 conducted in patients without cardiovascular disease, the
for the 12.0 to 12.5 g/dL and 14.0 g/dL strategies. It 95% CI appeared to exclude a 30% reduction in hospital-
remained in excess of $400,000 even when estimated ization associated with raising hemoglobin to 14.0 g/dL
EPO requirements were substantially reduced. (overall, 11% reduction; 95% CI, 28% reduction to 10%
Our base case scenario assumed that the majority of increase), and the mean number of days in hospital was
improvement in HRQOL was observed at hemoglobin actually not significantly higher in the normal hemoglo-
levels between 11.0 and 12.0 g/dL, compared with 9.5 to bin group (19.8 days vs. 13.8 days) (abstract; Foley RN
10.5 g/dL, and that higher hemoglobin levels tend to et al, J Am Soc Nephrol 13:432A, 2002).
increase overall quality of life to a lesser extent. This We chose to focus on data from randomized trials,
assumption is consistent with data from the only random- given the well-known limitations of observational stud-
ized trial, which compared utility scores associated with ies. Nonetheless, two papers based on observational data
hemoglobin targets of 9.5 to 10.5 g/dL and 14.0 g/dL from the USRDS are worthy of consideration. One such
(and showed no difference between the two) [18]. study suggests that achieved hemoglobin 12.0 g/dL is
To deal with the uncertainty surrounding the measure- associated with reduced rates of first hospitalization (by
ment of HRQOL for the different hemoglobin targets, 16% to 22% compared to hemoglobin 12.0 g/dL) [3].
we performed sensitivity analysis assuming that EPO However, the annual number of days in hospital is more
increased utility scores in a linear fashion with increasing economically relevant, and a second study from the same
hemoglobin concentration, with no maximum increase group shows that hospital days are not significantly re-
(utility method 2). In this analysis, the cost per QALY duced at hemoglobin levels 12.0 g/dL (compared with
to achieve the two higher hemoglobin targets was ap- 11.0 to 12.0 g/dL) [24]. For this reason, using USRDS
proximately $70,000 to $100,000 ($60,000 to $80,000 if data did not materially alter the cost-effectiveness of the
subcutaneous EPO was used). In our opinion, this sce- 12.0 to 12.5 g/dL and 14.0 g/dL targets (Table 5).
nario probably overestimates the increase in HRQOL Thus, current data suggest that higher hemoglobin
associated with higher hemoglobin targets, since the im- targets are unlikely to reduce hospitalization sufficiently
provement associated with the 14.0 g/dL strategy in this to offset the additional cost of EPO. However, this con-
model is comparable to that reported by hemodialysis clusion may require reevaluation if new randomized tri-
patients who receive renal transplants [23]. als indicate that higher hemoglobin targets significantly
Although our study could be criticized because extrap- reduce hospitalization rates, especially in people without
established cardiovascular disease.olation from a generic HRQOL instrument to utility
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Those unfamiliar with decision analysis may find the improvements in HRQOL. We have attempted to deal
modeling and statistic techniques to be complex and with these issues through extensive sensitivity analyses.
nontransparent. A simple model can approximate the Moreover, the consistency of our conclusions across a
results of our Markov analysis. Treatment with EPO to wide range of scenarios suggests that this imprecision
achieve a target hemoglobin of 11.0 to12.0 g/dL would did not adversely affect our results. Although our analy-
be expected to improve utility by 0.046 (compared with sis was conducted from the perspective of the health
9.5 to 10.5 g/dL), meaning that 22 patients (1/0.046) would care purchaser, the absence of evidence that EPO use
need to be treated to the higher target to realize a gain increases employment rates in hemodialysis patients
of 1 QALY. Our model predicts that the 11.0 to 12.0 g/dL makes it unlikely that adopting a societal perspective
target would require 1555 additional units of intravenous would have changed our results [32, 33].
EPO per treatment, at a total additional cost of $2435
annually. According to this calculation, the cost per
CONCLUSIONQALY gained by the 11.0 to 12.0 g/dL target is $52,938,
which is very similar to the result in Table 3. We found that dosing intravenous EPO to achieve
Given the disproportionate increase in EPO require- hemoglobin targets of 11.0 to 12.0 g/dL is associated with
ments at higher target hemoglobin levels, there may be an incremental cost per QALY gained of approximately
appreciable savings in cost associated with aiming for $50, 000 to $60,000 in hemodialysis patients, compared
the lower rather than the upper end of the 11.0 to 12.0 with a hemoglobin target of 9.5 to 10.5 g/dL. Use of the
g/dL target. As expected, use of the more efficient subcu- subcutaneous rather than intravenous route to adminis-
taneous route of administration resulted in improved ter EPO resulted in modest improvements in cost-effec-
cost-effectiveness ratios under all scenarios, which was tiveness, suggesting that it should be more widely used.
particularly relevant for the 11.0 to 12.0 g/dL strategy. In contrast, aiming for hemoglobin targets in excess of
This finding reinforces current recommendations to ad- 12.0 g/dL appears to be associated with unfavorable cost-
minister EPO subcutaneously [7, 19], and suggests that effectiveness ratios. Our findings suggest that such tar-
financial incentives encouraging the use of intravenous gets should not be recommended unless additional ran-
EPO should be removed. Using strategies such as these domized trials indicate that they substantially reduce the
to reduce inefficient expenditures in the hemodialysis risk of hospitalization or dramatically increase HRQOL.
population is important, since this money could be used
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Recent discrepancies between hypothesis-generating
analyses of observational data and subsequent large pro-
spective trials in dialysis patients highlight the impor- APPENDIX 1: ESTIMATION OF UTILITY
tance of using data from randomized studies to formulate SCORES ASSOCIATED WITH THE HIGHER
health policy [27, 28]. There is surprisingly little informa- HEMOGLOBIN TARGETS
tion from randomized trials to support current recom- Utility method 1
mendations for hemoglobin targets in hemodialysis pa-
The first method used the SF-36 results that were obtained in the
tients [7–9]. Despite this, the proportion of hemodialysis largest randomized trial that compared hemoglobin targets of 9.5 to
10.5 g/dL with 14.0 g/dL. In that study, the only dimension of the SF-36patients achieving specific hemoglobin levels has been
that improved was the physical function dimension [17]. Using theadopted as a measure of the quality of care [29]. This
conversion method of Fryback et al [38], we estimate the extent ofmay be due to the appeal of the clinical practice guide- improvement in utility scores that would be expected due to an incre-
lines, which have not addressed the economic implica- ment in only the physical function dimension of the SF-36 for the 12.0
to 12.5 g/dL target (increase of 0.43%) and the 14.0 g/dL target (increasetions of the hemoglobin targets in any detail. Our data
of 1.45%) (both compared with the 11.0 to 12.0 g/dL strategy).suggest that additional randomized trials are necessary
before hemoglobin targets in excess of 11.0 to 12.0 g/dL Utility method 2
are considered, and that substantial incremental clinical
In the second method, which was very favorable to higher target
benefit would be required to make such strategies an hemoglobin strategies, we assumed a continuing linear increase in
efficient use of resources. utility scores (i.e., a 3.7% increase in utility scores for the 12.0 to 12.5
g/dL target and a 12.3% increase in utility scores for the 14.0 g/dLWe performed our study in accordance with current
group, both compared to the 11.0 to 12.0 g/dL strategy). The firstguidelines for economic evaluations [30, 31]. In addition, method is likely more realistic than the second, since a randomized
wherever uncertainty exists, we have attempted to make trial showed no improvement in utility scores between the low (9.5 to
11.0 g/dL) and high (13.0 to 14.0 g/dL) hemoglobin arms [18]. As aour assumptions favorable to the higher hemoglobin
point of reference, this model assumed that the improvement in utilitystrategies, which we believe makes our results particu-
associated with an increase in hemoglobin from 10 to 14 g/dL (0.197)
larly compelling. Limitations of our study include the was comparable to that associated with successful renal transplantation
(0.195) [23].relative imprecision of the estimates of EPO use and
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11. United States Renal Data System (USRDS) Annual Data Report,APPENDIX 2: ESTIMATION OF EPO
Bethesda, MD, National Institutes of Health, National InstituteDOSE REQUIREMENTS of Diabetes and Digestive and Kidney Diseases, 2001
12. Canadian Erythropoietin Study Group: Association betweenMethod A
recombinant human erythropoietin and quality of life and exercise
A literature search was performed to identify all randomized trials capacity of patients receiving haemodialysis. Br Med J 300:573–578,
comparing different hemoglobin targets in EPO-treated hemodialysis 1990
patients, and five randomized studies, all of which used EPO , were 13. Besarab A, Aslam M: Should the hematocrit (hemoglobin) be
identified [17, 18, 39–41]. A dose-response curve for data on actual normalized in pre-ESRD or dialysis patients? Yes! Blood Purif
EPO usage per target hemoglobin strategy was plotted using data from 19:168–174, 2002
these five trials. Since the relationship between target hemoglobin and 14. Sonnenberg FA, Beck JR: Markov models in medical decision
EPO dose appeared to be exponential (reflecting disproportionate making: A practical guide. Med Decis Making 13:322–338, 1993
increases in EPO requirements at higher hemoglobin targets [2]), the 15. Gold MR, Siegel JE, Russell LB, Weinstein M: Cost Effective-
data was log-transformed, and linear regression–weighted by study size ness in Health and Medicine, New York, Oxford University Press,was performed, after adjustment for route of EPO administration (Fig. 1, 1996Table 2). 16. Manns BJ, Johnson JA, Taub KJ, et al: Quality of Life in PatientsWe estimated that intravenous administration (compared to subcu- with End-Stage Renal Disease on Hemodialysis or Peritoneal Dial-taneous administration) would require 14% higher doses, based on
ysis: What Are the Important Determinants?, Edmonton, Canada,the lower limit of the 95% CI from a good-quality randomized trial
Institute of Health Economics, 2002that addressed this issue [37]. For our baseline analysis, all EPO doses
17. Besarab A, Bolton WK, Browne JK, et al: The effects of normalwere based on intravenous administration, to reflect the route that is
as compared with low hematocrit values in patients with cardiactypically used in hemodialysis units in the United States [42]. Estimated
disease who are receiving hemodialysis and epoetin. N Engl J MedEPO requirements for each strategy were obtained from the resulting
339:584–590, 1998dose-response regression equation, and expressed as units per treat-
18. Foley RN, Parfrey PS, Morgan J, et al: Effect of hemoglobinment, assuming three times a week hemodialysis.
levels in hemodialysis patients with asymptomatic cardiomyopathy.
Kidney Int 58:1325–1335, 2000
Method B 19. Hynes DM, Stroupe KT, Greer JW, et al: Potential cost savings
We assumed that EPO for each of the four hemoglobin targets would of erythropoietin administration in end-stage renal disease. Am J
be given by the subcutaneous route, reducing the EPO requirements for Med 112:169–175, 2002
each strategy accordingly. 20. Drug Topics Red Book, Montvail, NJ, Medical Economics Com-
pany Incorporated, 2001
21. United States Renal Data System (USRDS) Annual Data Report,Method C
Bethesda, MD, National Institutes of Health, National Institute
We assumed that the EPO dose needed to reach each target in of Diabetes and Digestive and Kidney Diseases, 1999clinical practice was represented by the lower limit of the 95% CI of 22. Lee J, Manns BJ, Taub KJ, et al: Cost analysis of ongoing carethe estimate used in the reference case, to address the unlikely event
of patients with end-stage renal disease: The impact of dialysisthat our model substantially overestimated EPO requirements (see
modality and dialysis access. Am J Kidney Dis 40:611–622, 2002Table 5).
23. Laupacis A, Keown P, Pus N, et al: A study of the quality of life
and cost-utility of renal transplantation. Kidney Int 50:235–242,
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